Coronavirus disease 2019(COVID-19)has become a worldwide pandemic.Hospitalized patients of COVID-19 suffer from a high mortality rate,motivating the development of convenient and practical methods that allow clinician...Coronavirus disease 2019(COVID-19)has become a worldwide pandemic.Hospitalized patients of COVID-19 suffer from a high mortality rate,motivating the development of convenient and practical methods that allow clinicians to promptly identify high-risk patients.Here,we have developed a risk score using clinical data from 1479 inpatients admitted to Tongji Hospital,Wuhan,China(development cohort)and externally validated with data from two other centers:141 inpatients from Jinyintan Hospital,Wuhan,China(validation cohort 1)and 432 inpatients from The Third People’s Hospital of Shenzhen,Shenzhen,China(validation cohort 2).The risk score is based on three biomarkers that are readily available in routine blood samples and can easily be translated into a probability of death.The risk score can predict the mortality of individual patients more than 12 d in advance with more than 90%accuracy across all cohorts.Moreover,the Kaplan-Meier score shows that patients can be clearly differentiated upon admission as low,intermediate,or high risk,with an area under the curve(AUC)score of 0.9551.In summary,a simple risk score has been validated to predict death in patients infected with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2);it has also been validated in independent cohorts.展开更多
Since the first reported case of monkeypox in the UK in May 2022,there has been an upward trend in monkeypox cases and a global outbreak.However,reports of severe cases are relatively limited.In this study,we report a...Since the first reported case of monkeypox in the UK in May 2022,there has been an upward trend in monkeypox cases and a global outbreak.However,reports of severe cases are relatively limited.In this study,we report a case of severe monkeypox in a patient with HIV.The patient presented with skin lesions that started on his face and around the penis and persisted for several months.Throughout the course of the disease,he received systematic symp-tomatic supportive treatment,topical remedies,and special care for the rash.He also underwent cidofovir antiviral therapy and smallpox‐vaccinated healthy population‐derived plasma therapy in succession,with the condition ultimately showing improvement after plasma treatment.After more than 3 months of hospitalization,he fully recovered.To the best of our knowledge,this is the first reported use of smallpox‐vaccinated healthy population‐derived plasma in the treatment of severe monkeypox cases.展开更多
Introduction COVID-19,caused by SARS-CoV-2,is a highly contagious disease.1 By April 8,2020,more than 1,350,000 patients were diagnosed with COVID-19 globally,with more than 79,000 deaths worldwide attributable to the...Introduction COVID-19,caused by SARS-CoV-2,is a highly contagious disease.1 By April 8,2020,more than 1,350,000 patients were diagnosed with COVID-19 globally,with more than 79,000 deaths worldwide attributable to the disease.2 Recent clinical data reported that mild and critical patients manifested different symptoms.Most of the mild patients with COVID-19 had symptoms such as fever,cough,and mild pneumonia,whereas the critical cases presented dyspnea,respiratory failure,sepsis,organ dysfunction,and even eventual death.展开更多
基金supported by the Special Fund for Novel Coronavirus Pneumonia from the Department of Science and Technology of Hubei Province(2020FCA035)the Fundamental Research Funds for the Central Universities,Huazhong University of Science and Technology(2020kfyXGYJ023).
文摘Coronavirus disease 2019(COVID-19)has become a worldwide pandemic.Hospitalized patients of COVID-19 suffer from a high mortality rate,motivating the development of convenient and practical methods that allow clinicians to promptly identify high-risk patients.Here,we have developed a risk score using clinical data from 1479 inpatients admitted to Tongji Hospital,Wuhan,China(development cohort)and externally validated with data from two other centers:141 inpatients from Jinyintan Hospital,Wuhan,China(validation cohort 1)and 432 inpatients from The Third People’s Hospital of Shenzhen,Shenzhen,China(validation cohort 2).The risk score is based on three biomarkers that are readily available in routine blood samples and can easily be translated into a probability of death.The risk score can predict the mortality of individual patients more than 12 d in advance with more than 90%accuracy across all cohorts.Moreover,the Kaplan-Meier score shows that patients can be clearly differentiated upon admission as low,intermediate,or high risk,with an area under the curve(AUC)score of 0.9551.In summary,a simple risk score has been validated to predict death in patients infected with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2);it has also been validated in independent cohorts.
基金Science and Technology Research Projects of Shenzhen,Grant/Award Number:JSGG20220606141001003National Key Research and Development Program of China,Grant/Award Number:2022YFC2304403,2022YFC2304404+2 种基金National Natural Science Foundation of China,Grant/Award Number:81971915,82272318Shenzhen Fund for Guangdong Provincial High‐level Clinical Key Specialties,Grant/Award Number:No.SZGSP011Shenzhen Fund for Guangdong Provincial High‐level Clinical Key Specialties(No.SZGSP011)。
文摘Since the first reported case of monkeypox in the UK in May 2022,there has been an upward trend in monkeypox cases and a global outbreak.However,reports of severe cases are relatively limited.In this study,we report a case of severe monkeypox in a patient with HIV.The patient presented with skin lesions that started on his face and around the penis and persisted for several months.Throughout the course of the disease,he received systematic symp-tomatic supportive treatment,topical remedies,and special care for the rash.He also underwent cidofovir antiviral therapy and smallpox‐vaccinated healthy population‐derived plasma therapy in succession,with the condition ultimately showing improvement after plasma treatment.After more than 3 months of hospitalization,he fully recovered.To the best of our knowledge,this is the first reported use of smallpox‐vaccinated healthy population‐derived plasma in the treatment of severe monkeypox cases.
基金We thank the patients,nurses,and physicians who pro-vided care for the patients,and the investigators at the Third People's Hospital of Shenzhen.This work is supported by grants from the Science and Technology Innovation Committee of Shenzhen Municipality(202002073000001)National Key Research and Development Program(2020YFC0841700)+1 种基金High-level University Fund(no.G02386301,G02386401)Guangdong Natural Science Foundation Joint Fund(no.2019A1515111038).
文摘Introduction COVID-19,caused by SARS-CoV-2,is a highly contagious disease.1 By April 8,2020,more than 1,350,000 patients were diagnosed with COVID-19 globally,with more than 79,000 deaths worldwide attributable to the disease.2 Recent clinical data reported that mild and critical patients manifested different symptoms.Most of the mild patients with COVID-19 had symptoms such as fever,cough,and mild pneumonia,whereas the critical cases presented dyspnea,respiratory failure,sepsis,organ dysfunction,and even eventual death.
